<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013272</url>
  </required_header>
  <id_info>
    <org_study_id>HKUHEP-01</org_study_id>
    <nct_id>NCT01013272</nct_id>
  </id_info>
  <brief_title>Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load</brief_title>
  <official_title>Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis B and treated with entecavir for over 6 months (with no
      previous other antiviral treatment) will be invited to participate in this study. They will
      be eligible if their liver tests are normal and their viral load is undetectable. Patients
      will be switched to lamivudine treatment to assess whether lamivudine can maintain adequate
      suppression of the hepatitis B virus after successful treatment with entecavir. Patients will
      be monitored closely after switching treatment at 1 months and then every 3 monthly. If there
      is any evidence of increase in viral load then patients will be given the option of changing
      back to entecavir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the efficacy of lamivudine therapy in patients with prior entecavir treatment with undetectable viral load</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the chance of lamivudine resistance in patients with prior entecavir treatment with undetectable viral load</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ongoing entecavir 0.5mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switch to lamivudine 100mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5mg orally daily</description>
    <arm_group_label>Entecavir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 100mg orally, daily</description>
    <arm_group_label>Lamivudine</arm_group_label>
    <other_name>Zeffix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis B treated with entecavir for 6 months or more

          -  Normal ALT

          -  Undetectable HBV DNA by Roche Taqman PCR Assay

          -  No other previous therapy with nucleoside/nucleotide analogues

        Exclusion Criteria:

          -  Presence of other liver diseases including hepatitis C co-infection, autoimmune
             hepatitis , primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver
             disease, and Wilson's disease

          -  History of hepatocellular carcinoma

          -  History of decompensated liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Fung, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>James Yan Yue Fung</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>entecavir</keyword>
  <keyword>lamivudine</keyword>
  <keyword>sequential therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

